MPM Bioimpact LLC Has $22.21 Million Holdings in Natera, Inc. $NTRA

Key Points

• MPM Bioimpact LLC has reduced its stake in Natera, Inc. by 2.2%, now holding $22.21 million worth of shares, which represents approximately 3.8% of its total investments.
• Several institutional investors, including Price T Rowe Associates and JPMorgan Chase, significantly increased their positions in Natera during the first quarter of 2023, indicating strong interest in the company.
• Natera's recent earnings report showed a revenue increase of 32.2% year-over-year, though it reported a loss of ($0.74) per share, underperforming against analysts' expectations.

MPM Bioimpact LLC trimmed its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 2.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,047 shares of the medical research company's stock after selling 3,579 shares during the quarter. Natera makes up approximately 3.8% of MPM Bioimpact LLC's holdings, making the stock its 7th largest position. MPM Bioimpact LLC owned 0.12% of Natera worth $22,208,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NTRA. Price T Rowe Associates Inc. MD boosted its position in Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the period. Nuveen LLC acquired a new position in Natera during the 1st quarter valued at approximately $113,375,000. JPMorgan Chase & Co. boosted its position in Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock valued at $1,041,055,000 after purchasing an additional 660,538 shares during the period. SG Americas Securities LLC boosted its position in Natera by 8,233.5% during the 1st quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock valued at $56,270,000 after purchasing an additional 393,149 shares during the period. Finally, Maverick Capital Ltd. boosted its position in Natera by 19.7% during the 1st quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company's stock valued at $231,173,000 after purchasing an additional 268,715 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. UBS Group boosted their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Royal Bank Of Canada boosted their price objective on Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 price target for the company in a research report on Monday, July 28th. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Finally, Stephens reiterated an "overweight" rating and set a $183.00 price target on shares of Natera in a research report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $193.19.

Natera Stock Performance

Shares of NTRA stock opened at $168.25 on Tuesday. Natera, Inc. has a 1 year low of $110.57 and a 1 year high of $183.00. The stock has a fifty day moving average of $154.36 and a two-hundred day moving average of $153.77. The firm has a market capitalization of $23.09 billion, a PE ratio of -88.09 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's quarterly revenue was up 32.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. Equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 5,807 shares of the business's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $132.88, for a total transaction of $771,634.16. Following the sale, the chief executive officer directly owned 163,593 shares of the company's stock, valued at $21,738,237.84. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gail Boxer Marcus sold 2,496 shares of the business's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $133.17, for a total value of $332,392.32. Following the sale, the director directly owned 5,763 shares in the company, valued at $767,458.71. This trade represents a 30.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 49,594 shares of company stock valued at $7,312,528 over the last ninety days. Company insiders own 5.63% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.